المؤلفون: Young, Philip, Elghawy, Omar, Mock, Joseph, Wynter, Emmett, Gentzler, Ryan D., Martin, Linda W., Novicoff, Wendy, Hall, Richard

المصدر: Current Oncology; Jan2024, Vol. 31 Issue 1, p260-273, 14p

مصطلحات موضوعية: NON-small-cell lung carcinoma, IMMUNE checkpoint inhibitors, TREATMENT duration, OVERALL survival, IPILIMUMAB, BUPRENORPHINE, OPIOIDS

الشركة/الكيان: UNIVERSITY of Virginia

مستخلص: Immune checkpoint inhibitors (ICI) have significantly improved outcomes in advanced non-small cell lung cancer (NSCLC). We evaluated the effect of opioid use on outcomes in patients receiving ICI either alone or with chemotherapy. We conducted a retrospective review of 209 patients with advanced NSCLC who received an ICI at the University of Virginia between 1 February 2015 and 1 January 2020. We performed univariate and multivariate analyses to evaluate the impact of opioid use on duration of therapy (DOT) and overall survival (OS). Patients with no or low opioid use (n = 172) had a median DOT of 12.2 months (95% CI: 6.9–17.4) compared to 1.9 months (95% CI: 1.8–2.0) for those with high opioid use (n = 37, HR 0.26 95% CI: 0.17–0.40, p < 0.001). Patients with no or low opioid use had a median OS of 22.6 months (95% CI: 14.8–30.4) compared to 3.8 months (95% CI: 2.7–4.9) for those with high opioid use (HR 0.26 95% CI: 0.17–0.40 p < 0.001). High opioid use was associated with a shorter DOT and worse OS. This difference remained significant when accounting for possible confounding variables. These data warrant investigation of possible mechanistic interactions between opioids, tumor progression, and ICIs, as well as prospective evaluation of opioid-sparing pain management strategies, where possible. [ABSTRACT FROM AUTHOR]

: Copyright of Current Oncology is the property of MDPI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

المؤلفون: Sarkaria, Inderpal S., Martin, Linda W., Rice, David C., Blackmon, Shanda H., Slade, Herbert B., Singhal, Sunil

المصدر: Journal of Thoracic & Cardiovascular Surgery; Dec2023, Vol. 166 Issue 6, pe468-e478, 11p

مستخلص: The study objective was to determine the clinical utility of pafolacianine, a folate receptor–targeted fluorescent agent, in revealing by intraoperative molecular imaging folate receptor α positive cancers in the lung and narrow surgical margins that may otherwise be undetected with conventional visualization. In this Phase 3, 12-center trial, 112 patients with suspected or biopsy-confirmed cancer in the lung scheduled for sublobar pulmonary resection were administered intravenous pafolacianine within 24 hours before surgery. Participants were randomly assigned to surgery with or without intraoperative molecular imaging (10:1 ratio). The primary end point was the proportion of participants with a clinically significant event, reflecting a meaningful change in the surgical operation. No drug-related serious adverse events occurred. One or more clinically significant event occurred in 53% of evaluated participants compared with a prespecified limit of 10% (P <.0001). In 38 participants, at least 1 event was a margin 10 mm or less from the resected primary nodule (38%, 95% confidence interval, 28.5-48.3), 32 being confirmed by histopathology. In 19 subjects (19%, 95% confidence interval, 11.8-28.1), intraoperative molecular imaging located the primary nodule that the surgeon could not locate with white light and palpation. Intraoperative molecular imaging revealed 10 occult synchronous malignant lesions in 8 subjects (8%, 95% confidence interval, 3.5-15.2) undetected using white light. Most (73%) intraoperative molecular imaging–discovered synchronous malignant lesions were outside the planned resection field. A change in the overall scope of surgical procedure occurred for 29 of the subjects (22 increase, 7 decrease). Intraoperative molecular imaging with pafolacianine improves surgical outcomes by identifying occult tumors and close surgical margins. Methods, results, and implications are presented in a single graphical abstract. [Display omitted] [ABSTRACT FROM AUTHOR]

: Copyright of Journal of Thoracic & Cardiovascular Surgery is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

المؤلفون: Azari, Feredun, Kennedy, Gregory, Bernstein, Elizabeth, Hadjipanayis, Costas, Vahrmeijer, Alexander L., Smith, Barbara L., Rosenthal, Eben, Sumer, Baran, Tian, Jie, Henderson, Eric R., Lee, Amy, Nguyen, Quyen, Gibbs, Summer L., Pogue, Brian W., Orringer, Daniel A., Charalampaki, Patra, Martin, Linda W., Tanyi, Janos L., Kenneth Lee, Major, Lee, John Y. K., Singhal, Sunil

المصدر: Journal of Biomedical Optics ; volume 26, issue 05 ; ISSN 1083-3668

الإتاحة: https://doi.org/10.1117/1.jbo.26.5.050901Test
https://www.spiedigitallibrary.org/journalArticle/Download?urlId=10.1117%2F1.JBO.26.5.050901Test

المؤلفون: Allaix, Marco E., Andrade, Vera Lucia Angelo, Azevedo, Renata, Barbieri, Lavinia, Costantini, Andrea, Costantini, Mario, Desai, Nirmal, El Moheb, Mohamad, Herbella, Fernando Augusto Mardiros, Hermann, Lauren, Huffman, Julie, Hunold, Thomas, Kaperak, Christopher, Martin, Linda W., Mervak, Benjamin M., Neto, Rafael Melillo Laurino, Olinger, Kristen, Patti, Marco G., Puccetti, Francesco, Rebecchi, Fabrizio, Robert, Kavitt, Rosati, Riccardo, Salvador, Renato, Schlottmann, Francisco, Ugliono, Elettra, Veloso, Júlio César de Soares, Viktorsson, Sindri A., Wang, Wenfei, Watson, Thomas J., Young, Andrew M., Young, Chris

المصدر: Dysphagia ; page xi-xii ; ISBN 9780323998659

الإتاحة: https://doi.org/10.1016/b978-0-323-99865-9.50006-2Test
https://api.elsevier.com/content/article/PII:B9780323998659500062?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:B9780323998659500062?httpAccept=text/plainTest

المؤلفون: Young, Andrew M., El Moheb, Mohamad, Viktorsson, Sindri A., Martin, Linda W.

المصدر: Dysphagia ; page 173-182 ; ISBN 9780323998659

الإتاحة: https://doi.org/10.1016/b978-0-323-99865-9.00004-xTest
https://api.elsevier.com/content/article/PII:B978032399865900004X?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:B978032399865900004X?httpAccept=text/plainTest

المؤلفون: Krebs, Elizabeth D., Mehaffey, J. Hunter, Sarosiek, Bethany M., Blank, Randal S., Lau, Christine L., Martin, Linda W.

المساهمون: National Cancer Institute, National Institutes of Health

المصدر: The Journal of Thoracic and Cardiovascular Surgery ; volume 159, issue 1, page 284-294.e1 ; ISSN 0022-5223

مصطلحات موضوعية: Cardiology and Cardiovascular Medicine, Pulmonary and Respiratory Medicine, Surgery

الإتاحة: https://doi.org/10.1016/j.jtcvs.2019.08.036Test
https://api.elsevier.com/content/article/PII:S0022522319317714?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S0022522319317714?httpAccept=text/plainTest

المؤلفون: Martin, Linda W.

المصدر: The Journal of Thoracic and Cardiovascular Surgery ; volume 160, issue 3, page 878 ; ISSN 0022-5223

مصطلحات موضوعية: Cardiology and Cardiovascular Medicine, Pulmonary and Respiratory Medicine, Surgery

الإتاحة: https://doi.org/10.1016/j.jtcvs.2020.02.113Test
https://api.elsevier.com/content/article/PII:S0022522320305651?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S0022522320305651?httpAccept=text/plainTest

المؤلفون: Haywood, Nathan, Nickel, Ian, Zhang, Aimee, Byler, Matthew, Scott, Erik, Julliard, Walker, Blank, Randal S., Martin, Linda W.

المصدر: Thoracic Surgery Clinics ; volume 30, issue 3, page 259-267 ; ISSN 1547-4127

مصطلحات موضوعية: Pulmonary and Respiratory Medicine, Surgery

الإتاحة: https://doi.org/10.1016/j.thorsurg.2020.04.005Test
https://api.elsevier.com/content/article/PII:S1547412720300311?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S1547412720300311?httpAccept=text/plainTest

المؤلفون: Potter, Alexandra L., Costantino, Christina L., Suliman, Raiya A., Haridas, Chinmay S., Senthil, Priyanka, Kumar, Arvind, Mayne, Nicholas R., Panda, Nikhil, Martin, Linda W., Yang, Chi-Fu Jeffrey

المصدر: Annals of Thoracic Surgery; Oct2023, Vol. 116 Issue 4, p684-692, 9p

مستخلص: The objective of this study was to evaluate patterns, predictors, and long-term outcomes of recurrent disease after complete resection for early-stage non-small cell lung cancer (NSCLC) using the National Lung Screening Trial (NLST). The frequency of recurrence in patients with pathologic stage I-II NSCLC who underwent complete resection (lobectomy or bilobectomy) in the NLST was evaluated. Predictors of increased risk of recurrence were assessed by Fine-Gray competing risks regression. Of the 497 patients meeting study inclusion criteria, 94 experienced a recurrence—a rate of 4.9 (95% CI, 4.0-6.0) per 100 person-years. The 5-year cumulative incidence of recurrence was 20.1% (95% CI, 16.5%-23.9%). Most patients experienced recurrences at distant sites alone (n = 47 [50.0%]) or at both locoregional and distant sites (n = 30 [31.9%]). The median time from resection to recurrence was 18.8 (10.6-30.7) months. The incidence rate of recurrence was significantly lower among patients with lung cancer detected by low-dose computed tomography screening during one of the three screening rounds of the NLST when compared with patients with lung cancer detected by chest radiography screening and patients with lung cancer not detected by any form of screening (ie, those diagnosed after a negative or missed screening exam and those diagnosed during follow-up after the three screening rounds of the NLST were completed) (P <.001). Median survival (from the date of recurrence) of patients with pathologic stage I and stage II disease who had recurrences at locoregional, distant, or both sites was 63.0, 23.1, and 9.8 months and 28.9, 8.7, and 10.2 months, respectively. In this analysis of NLST participants with completely resected stage I-II NSCLC, the 5-year cumulative incidence of recurrence was 20%. Nearly 82% of recurrences were at distant sites and associated with poor survival. [ABSTRACT FROM AUTHOR]

: Copyright of Annals of Thoracic Surgery is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

المؤلفون: Sarkaria, Inderpal S, Martin, Linda W, Rice, David C, Blackmon, Shanda H, Slade, Herbert B, Singhal, Sunil, ELUCIDATE Study Group, Louie (ELUCIDATE Study Group), Brian

المصدر: Articles, Abstracts, and Reports

مصطلحات موضوعية: washington, swedish, swedish cancer, Oncology, Pulmonology, Radiology

الوصف: OBJECTIVE: The study objective was to determine the clinical utility of pafolacianine, a folate receptor-targeted fluorescent agent, in revealing by intraoperative molecular imaging folate receptor α positive cancers in the lung and narrow surgical margins that may otherwise be undetected with conventional visualization. METHODS: In this Phase 3, 12-center trial, 112 patients with suspected or biopsy-confirmed cancer in the lung scheduled for sublobar pulmonary resection were administered intravenous pafolacianine within 24 hours before surgery. Participants were randomly assigned to surgery with or without intraoperative molecular imaging (10:1 ratio). The primary end point was the proportion of participants with a clinically significant event, reflecting a meaningful change in the surgical operation. RESULTS: No drug-related serious adverse events occurred. One or more clinically significant event occurred in 53% of evaluated participants compared with a prespecified limit of 10% (P < .0001). In 38 participants, at least 1 event was a margin 10 mm or less from the resected primary nodule (38%, 95% confidence interval, 28.5-48.3), 32 being confirmed by histopathology. In 19 subjects (19%, 95% confidence interval, 11.8-28.1), intraoperative molecular imaging located the primary nodule that the surgeon could not locate with white light and palpation. Intraoperative molecular imaging revealed 10 occult synchronous malignant lesions in 8 subjects (8%, 95% confidence interval, 3.5-15.2) undetected using white light. Most (73%) intraoperative molecular imaging-discovered synchronous malignant lesions were outside the planned resection field. A change in the overall scope of surgical procedure occurred for 29 of the subjects (22 increase, 7 decrease). CONCLUSIONS: Intraoperative molecular imaging with pafolacianine improves surgical outcomes by identifying occult tumors and close surgical margins.

العلاقة: https://digitalcommons.psjhealth.org/publications/7274Test; https://pubmed.ncbi.nlm.nih.gov/37019717Test/

الإتاحة: https://digitalcommons.psjhealth.org/publications/7274Test
https://pubmed.ncbi.nlm.nih.gov/37019717Test/